インターロイキン2受容体βサブユニット

WordNet

to remain unmolested, undisturbed, or uninterrupted -- used only in infinitive form; "let her be"
work in a specific place, with a specific subject, or in a specific function; "He is a herpetologist"; "She is our resident philosopher" (同)follow
have life, be alive; "Our great leader is no more"; "My grandfather lived until the end of war" (同)live
be identical to; be someone or something; "The president of the company is John Smith"; "This is my house"
happen, occur, take place; "I lost my wallet; this was during the visit to my parents house"; "There were two hundred people at his funeral"; "There was a lot of noise in the kitchen"
have the quality of being; (copula, used with an adjective or a predicate noun); "John is rich"; "This is not a good answer"
occupy a certain position or area; be somewhere; "Where is my umbrella?" "The toolshed is in the back"; "What is behind this behavior?"
spend or use time; "I may be an hour"
stake on the outcome of an issue; "I bet $100 on that new horse"; "She played all her money on the dark horse" (同)wager, play
the act of gambling; "he did it on a bet" (同)wager
maintain with or as if with a bet; "I bet she will be there!" (同)wager
second in order of importance; "the candidate, considered a beta male, was perceived to be unable to lead his party to victory"
the 2nd letter of the Greek alphabet
preliminary or testing stage of a software or hardware product; "a beta version"; "beta software"
a cellular structure that is postulated to exist in order to mediate between a chemical agent that acts on nervous tissue and the physiological response
any of several lymphokines that promote macrophages and killer T cells and B cells and other components of the immune system

PrepTutorEJDIC

《連結語として補語を伴なって…『である』,…だ,…です / 《位置・場所を表す語句を伴って》(…に)『ある』,いる(occupy a place or situation) / 〈物事が〉『存在する』,ある(exist);〈生物が〉生存する,生きている(live) / 行われる,起こる,発生する(take place, occur) / 存続する,そのままでいる(remain as before) / 《『be to』 do》 / …する予定である,…することになっている / …すべきだ / 《受動態の不定詞を伴って》…できる / 《命令》…するのだ / 《条件節に》…する意図がある / 《『if…were to』 do》…するとしたなら / 《『be』 do『ing』》《進行形》 / 《進行中の動作》…している,しつつある / 《近い未来》…しようとしている,するつもり / 《動作の反復》(いつも)…している / 《『be』+『他動詞の過去分詞』》《受動態》…される,されている / 《『be』+『自動詞の過去分詞』》《完了形》…した[状態にある]
『かけ』・(…との)かけ《+『with』+『名』》 / かけた物(金) / かけの対象 / 〈金・物〉'を'『かける』 / (かけ事・ゲームなどで)〈人〉‘と'『かけをする』《+『名』〈人〉+『on』+『名』》 / (…に)『かける』《+『on』(『against』)+『名』(one's do『ing』)》
ベータ(ギリシア語アルファベットの第2文字;B,β;英語のB,b に遭当)
=sense organ / 受信装置

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. リウマチ性疾患におけるサイトカインの役割 role of cytokines in rheumatic diseases
2. 複合免疫不全 combined immunodeficiencies
3. 成人における再発寛解型多発性硬化症の治療 treatment of relapsing remitting multiple sclerosis in adults
4. レフルノミドによる関節リウマチの治療 leflunomide in the treatment of rheumatoid arthritis
5. 成人におけるステロイド抵抗性およびステロイド依存性の潰瘍性大腸炎に対するアプローチ approach to adults with steroid refractory and steroid dependent ulcerative colitis

English Journal

Identifying the ERAD ubiquitin E3 ligases for viral and cellular targeting of MHC class I.

van den Boomen DJ1, Lehner PJ2.
Molecular immunology.Mol Immunol.2015 Dec;68(2 Pt A):106-11. doi: 10.1016/j.molimm.2015.07.005. Epub 2015 Jul 22.
The human cytomegalovirus (HCMV) US2 and US11 gene products hijack mammalian ER-associated degradation (ERAD) to induce rapid degradation of major histocompatibility class I (MHC-I) molecules. The rate-limiting step in this pathway is thought to be the polyubiquitination of MHC-I by distinct host ER
PMID 26210183

90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma.

Janik JE1, Morris JC1, O'Mahony D1, Pittaluga S2, Jaffe ES2, Redon CE3, Bonner WM3, Brechbiel MW4, Paik CH5, Whatley M5, Chen C5, Lee JH5, Fleisher TA6, Brown M6, White JD1, Stewart DM1, Fioravanti S1, Lee CC1, Goldman CK1, Bryant BR1, Junghans RP7, Carrasquillo JA5, Worthy T1, Corcoran E1, Conlon KC1, Waldmann TA8.
Proceedings of the National Academy of Sciences of the United States of America.Proc Natl Acad Sci U S A.2015 Oct 20;112(42):13045-50. doi: 10.1073/pnas.1516107112. Epub 2015 Oct 5.
Despite significant advances in the treatment of Hodgkin's lymphoma (HL), a significant proportion of patients will not respond or will subsequently relapse. We identified CD25, the IL-2 receptor alpha subunit, as a favorable target for systemic radioimmunotherapy of HL. The scientific basis for the
PMID 26438866

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Kappos L1, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, Kaufman M, Rose J, Greenberg S, Sweetser M, Riester K, O'Neill G, Elkins J.
The New England journal of medicine.N Engl J Med.2015 Oct 8;373(15):1418-28. doi: 10.1056/NEJMoa1501481.
BACKGROUND: Daclizumab high-yield process (HYP) is a humanized monoclonal antibody that binds to CD25 (alpha subunit of the interleukin-2 receptor) and modulates interleukin-2 signaling. Abnormalities in interleukin-2 signaling have been implicated in the pathogenesis of multiple sclerosis and other
PMID 26444729

Japanese Journal

Glucocorticoid-mediated inhibition of interleukin-2 receptor alpha and -beta subunit expression by human T cells

BATUMAN O. A.
Immunopharmacology 27, 43-55, 1994
NAID 30010516958

The interleukin 2 receptor (IL-2R): the IL-2R alpha subunit alters the function of the IL-2R beta subunit to enhance IL-2 binding and signaling by mechanism that do not require binding of IL-2 to IL-2R alpha subunit.